Skip to main content

Lyme Disease

6
Pipeline Programs
8
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
5
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%
+ 10 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
4 programs
1
1
AntibioticsPhase 31 trial
Lyme Disease XenodiagnosisPhase 11 trial
Evaluation and Follow-up of People With Tick-borne DiseasesN/A1 trial
Evaluation, Treatment, and Follow-up of Patients With Lyme DiseaseN/A1 trial
Active Trials
NCT04318925Withdrawn0Est. Nov 2023
NCT00028080Recruiting500
NCT01143558Completed45Est. Dec 2014
+1 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
3
VLA15Phase 31 trial
VLA15Phase 31 trial
VLA15Phase 31 trial
Active Trials
NCT07500506Not Yet Recruiting1,712Est. Dec 2026
NCT05477524Active Not Recruiting12,547Est. Dec 2025
NCT05634811Completed3,549Est. Jul 2025
Valneva
ValnevaAustria - Vienna
1 program
1
VLA15Phase 3
Adaptive Biotechnologies
1 program
T-Detect LymeN/A
IQVIA
IQVIADURHAM, NC
1 program
T-Detect LymeN/A1 trial
Active Trials
NCT04422314Completed893Est. Oct 2021
Moderna
ModernaCAMBRIDGE, MA
1 program
mRNA-1975PHASE_1_2RNA Therapeutic1 trial
Active Trials
NCT05975099Completed807Est. May 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsAntibiotics
PfizerVLA15
PfizerVLA15
PfizerVLA15
ModernamRNA-1975
Allergy TherapeuticsLyme Disease Xenodiagnosis
Allergy TherapeuticsEvaluation and Follow-up of People With Tick-borne Diseases
IQVIAT-Detect Lyme
Allergy TherapeuticsEvaluation, Treatment, and Follow-up of Patients With Lyme Disease

Clinical Trials (9)

Total enrollment: 20,108 patients across 9 trials

NCT00000937Allergy TherapeuticsAntibiotics

Study and Treatment of Post Lyme Disease (STOP-LD)

Est. completion: Nov 200555 patients
Phase 3Completed
NCT07500506PfizerVLA15

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

Start: Apr 2026Est. completion: Dec 20261,712 patients
Phase 3Not Yet Recruiting
NCT05634811PfizerVLA15

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Start: Dec 2022Est. completion: Jul 20253,549 patients
Phase 3Completed
NCT05477524PfizerVLA15

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

Start: Aug 2022Est. completion: Dec 202512,547 patients
Phase 3Active Not Recruiting
NCT05975099ModernamRNA-1975

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

Start: Jul 2023Est. completion: May 2025807 patients
Phase 1/2Completed
NCT01143558Allergy TherapeuticsLyme Disease Xenodiagnosis

Searching for Persistence of Infection in Lyme Disease

Start: Nov 2010Est. completion: Dec 201445 patients
Phase 1Completed
NCT04318925Allergy TherapeuticsEvaluation and Follow-up of People With Tick-borne Diseases

Evaluation and Follow-up of People With Tick-borne Diseases

Start: Nov 2023Est. completion: Nov 20230
N/AWithdrawn
NCT04422314IQVIAT-Detect Lyme

ImmuneSense Lyme Study

Start: Jul 2020Est. completion: Oct 2021893 patients
N/ACompleted
NCT00028080Allergy TherapeuticsEvaluation, Treatment, and Follow-up of Patients With Lyme Disease

Evaluation, Treatment, and Follow-up of Patients With Lyme Disease

Start: Jan 2002500 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 20,108 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.